StockData
Celularity Inc logo

Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30
$0.57−0.05 (-7.75%)

Close on Nov 17, 2026Market cap $18.53MP/E –Yield –

Celularity r&d expenses

Research and development expenses are spending on new products and technology.

Celularity's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.97M, down 12.5% year over year. For fiscal 2025 it was $15.03M, down 13.6% from the year before. The highest annual figure on record is $88.35M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.03M-13.6%
FY2024Dec 31, 2024$17.39M-42.9%
FY2023Dec 31, 2023$30.47M-61.1%
FY2022Dec 31, 2022$78.36M-11.3%
FY2021Dec 31, 2021$88.35M+67.6%
FY2020Dec 31, 2020$52.71M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.03M-39.5%
Q1 FY2026Mar 31, 2026$2.99M-19.7%
Q4 FY2025Dec 31, 2025$3.35M-12.6%
Q3 FY2025Sep 30, 2025$4.60M+17.4%
Q2 FY2025Jun 30, 2025$3.35M-11.8%
Q1 FY2025Mar 31, 2025$3.73M-36.2%
Q4 FY2024Dec 31, 2024$3.83M-26.1%
Q3 FY2024Sep 30, 2024$3.92M-54.5%
Q2 FY2024Jun 30, 2024$3.80M-77.6%
Q1 FY2024Mar 31, 2024$5.84M-46.8%
Q3 FY2023Sep 30, 2023$5.18M-74.5%
Q2 FY2023Jun 30, 2023$8.60M-66.1%
Q1 FY2023Mar 31, 2023$16.95M-21.8%
Q4 FY2022Dec 31, 2022$10.99M-55.5%
Q3 FY2022Sep 30, 2022$20.35M-14.4%
Q2 FY2022Jun 30, 2022$25.35M+10.6%
Q1 FY2022Mar 31, 2022$21.67M+27.6%
Q4 FY2021Dec 31, 2021$24.69M+77.3%
Q3 FY2021Sep 30, 2021$23.77M+111.9%
Q2 FY2021Jun 30, 2021$22.91M–
Q1 FY2021Mar 31, 2021$16.99M–
Q4 FY2020Dec 31, 2020$13.92M–
Q3 FY2020Sep 30, 2020$11.22M–

More Celularity figures

See a number that looks wrong?